Annick Mottet-Muhlethaler
Lausanne, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Erratum: Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.
Journal: JCO precision oncology
Published: July 16, 2026
Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.
Journal: JCO precision oncology
Published: July 01, 2026
Low number of neurosecretory vesicles in neuroblastoma impairs massive catecholamine release and prevents hypertension.
Journal: Frontiers in endocrinology
Published: August 25, 2022
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2021
The noradrenergic profile of plasma metanephrine in neuroblastoma patients is reproduced in xenograft mice models and arise from PNMT downregulation.
Journal: Oncotarget
Published: October 06, 2020
Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia.
Journal: Frontiers in oncology
Published: October 31, 2018
Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
Journal: BMC cancer
Published: June 09, 2016
Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
Journal: Oncotarget
Published: June 21, 2014
Last Updated: 09/26/2026